Wikisage, the free encyclopedia of the second generation, is digital heritage
Diacomit: Difference between revisions
Jump to navigation
Jump to search
m ((R)) |
No edit summary |
||
| (7 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
Diacomit <sup>®</sup>contains 250 mg stiripentol<ref>http://www.ema.europa.eu/docs/es_ES/document_library/EPAR_-_Product_Information/human/000664/WC500036518.pdf</ref><ref>A new type of anticonvulsant, stiripentol. Pharmacological profile and neurochemical study. Arzneimittelforschung. 1984; 34(2):199-204.</ref> | Diacomit <sup>®</sup>contains 250 mg [[stiripentol]]<ref>http://www.ema.europa.eu/docs/es_ES/document_library/EPAR_-_Product_Information/human/000664/WC500036518.pdf</ref><ref>A new type of anticonvulsant, stiripentol. Pharmacological profile and neurochemical study. Arzneimittelforschung. 1984; 34(2):199-204.</ref> | ||
<ref>[http://onlinelibrary.wiley.com/doi/10.1111/j.1528-1167.2006.00497.x/pdf Stiripentol, a Putative Antiepileptic Drug, Enhances the Duration of Opening of GABA<sub>A</sub>-Receptor Channels]</ref> | <ref>[http://onlinelibrary.wiley.com/doi/10.1111/j.1528-1167.2006.00497.x/pdf Stiripentol, a Putative Antiepileptic Drug, Enhances the Duration of Opening of GABA<sub>A</sub>-Receptor Channels]</ref> | ||
| Line 5: | Line 5: | ||
In December 2001 the European Medicines Agency (EMA) granted stiripentol orphan drug status (designation number EU/3/01/071) for the treatment of severe myoclonic epilepsy of infancy (Dravet's syndrome). On 4 January 2007, the EMA granted the drug a marketing authorisation that is valid throughout the European Union | In December 2001 the European Medicines Agency (EMA) granted stiripentol orphan drug status (designation number EU/3/01/071) for the treatment of severe myoclonic epilepsy of infancy ([[Dravet%27s_syndrome|Dravet's syndrome]]). On 4 January 2007, the EMA granted the drug a marketing authorisation that is valid throughout the European Union | ||
[[Dravet's syndrome]] does not exist data for combined therapy both valproic acid or [[clobazam]]<ref>Aras et al 2015</ref> | [[Dravet's syndrome]] does not exist data for combined therapy both [[valproic acid]] or [[clobazam]]<ref>[http://www.epilepsybehavior.com/article/S1525-5050(14)00698-2/pdf Aras et al 2015]</ref> | ||
==ATC== | ==ATC== | ||
| Line 12: | Line 12: | ||
http://www.whocc.no/atc_ddd_index/?code=N03AX17 | http://www.whocc.no/atc_ddd_index/?code=N03AX17 | ||
{{refs}} | |||
[[Category:GABAA_receptor_positive_allosteric_modulators]] | |||
Latest revision as of 23:36, 24 August 2020
Diacomit ®contains 250 mg stiripentol[1][2]
-Stiripentol_Structural_Formulae_V.1.svg.png)
In December 2001 the European Medicines Agency (EMA) granted stiripentol orphan drug status (designation number EU/3/01/071) for the treatment of severe myoclonic epilepsy of infancy (Dravet's syndrome). On 4 January 2007, the EMA granted the drug a marketing authorisation that is valid throughout the European Union
Dravet's syndrome does not exist data for combined therapy both valproic acid or clobazam[4]
ATC
http://www.whocc.no/atc_ddd_index/?code=N03AX17
| References: |
|